Lakefront Biotherapeutics NV LKFT
34.09 USD +1.94 (+6.03%)
At closeNov 4, 2026, 4:01 PM EST
34.09 0.00 0.00%
After hours · Nov 4, 4:01 PM ET
32.85 Day range 34.13
25.68 52-week range 36.24
- YTD
- +4.25%
- 1 year
- +11.92%
Financial health
Altman Z-Score
15.28 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A+5 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 5
- P/E 4
- P/B 5
Valuation
P/E 5.7×
FY 2021 5y median 5.7× FY 2025
P/S 1.6×
FY 2021 5y median 10.1× FY 2025
P/B 0.6×
FY 2021 5y median 0.0× FY 2025
P/FCF -6.8×
FY 2021 5y median 0.0× FY 2025
EV/EBITDA 4.9×
FY 2021 5y median 0.0× FY 2025
EV/Sales 1.6×
FY 2021 5y median 0.0× FY 2025
FCF Yield -14.8%
FY 2021 5y median 0.0% FY 2025
Profitability
Gross Margin 97.3%
FY 2021 5y median 97.3% FY 2025
Operating Margin 45.1%
FY 2021 5y median -54.3% FY 2025
Net Margin 28.9%
FY 2021 5y median 26.9% FY 2025
ROE 9.9%
FY 2021 5y median 0.0% FY 2025
ROIC 15.4%
FY 2021 5y median 0.0% FY 2025
ROA 9.4%
FY 2021 5y median 0.0% FY 2025
Growth (YoY)
Revenue 303.5%
FY 2021 FY 2025
Operating Income 366.2%
FY 2021 FY 2025
EPS (diluted) 334.8%
FY 2021 FY 2025
Free Cash Flow 0.0%
FY 2021 FY 2025
Financial Health
Current Ratio 20.1×
FY 2021 5y median 0.0× FY 2025
Quick Ratio 20.0×
FY 2021 5y median 0.0× FY 2025
Debt / Equity 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA -0.2×
FY 2021 5y median 0.0× FY 2025
Interest Coverage 226×
FY 2021 5y median -19.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31